17

TAURUS ASSET MANAGEMENT COMPANY LIMITED CIN: U67190MH1993PLC073154

Head Office & Regd Office : 3rd Floor, 301-304, Chandravillas Co-op Premises Society Ltd., AML Centre 2, 8 Mahal Industrial Estate, Off. Mahakali Caves Road, Andheri-East, Mumbai - 400 093 Tel: 022 - 6624 2700

Email: customercare@taurusmutualfund.com A copy of SAI, SIDs and KIMs of the schemes of Taurus Mutual Fund along with application form may be obtained from Fund's website. www.taurusmutualfund.com



NOTICE

Hosting of Unaudited Half Yearly Results for the half-year ended 30th September 2024

Notice is hereby given to the Investors / Unit holders of all the Scheme(s) of Taurus Mutual Fund (the Fund) that in accordance with Regulation 59 of the SEBI (Mutual Funds) Regulations, 1996 read with SEBI (Mutual Funds) (Second Amendment) Regulations 2012 vide SEBI Gazette Notification dated 26th September 2012, the Unaudited Financial Results of all the Schemes of the Fund for the half-year ended September 30, 2024 have been hosted on the fund's website: www.taurusmutualfund.com

Investors/Unitholders may accordingly view/download the results from the website: https://www.taurusmutualfund.com/financials For Taurus Asset Management Company Ltd.

(Investment Manager for Taurus Mutual Fund)

Place: Mumbai Date: October 25, 2024 Notice No. 07/2024-2025

**Authorised Signatory** Mutual Fund investments are subject to market risks, read all scheme related

documents carefully.

**MO7CHIS** 

### MOSCHIP TECHNOLOGIES LIMITED CIN: L31909TG1999PLC032184

Regd Office: 7th Floor, "My Home Twitza", Hyderabad Knowledge City, Hyderabad - 500081. Tel: +91 40 66229292 email: investorrelations@moschip.com website:https://moschip.com

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS

### FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2024 All amounts in lakhs, except for EPS

AMICONGA AWARAN		Quarter ende	d	Half ye	Year ended	
Particulars	30-Sep-24 Unaudited	30-Jun-24 Unaudited	30-Sep-23 Unaudited	30-Sep-24 Unaudited	30-Sep-23 Unaudited	
Total Income	12,663.14	8,185.19	7,269.73	20,848.33	13,136.69	29,714.97
Net profit for the period / year (before	CHARLES WAS COME.		040019899999999	P 1500 (0.150) (0.90) (0.70)		CONTRACTOR CONTRACTOR
tax and exceptional item)	973.17	410.47	396.09	1,383.64	727.20	1,132.65
Net profit for the period / year (before	#047W600		2000 000 000 000 000 000 000 000 000 00	200000000000000000000000000000000000000		DVI C SESSON
tax and after exceptional item)	973.17	410.47	396.09	1,383.64	727.20	1,132.65
Net profit for the period / year (after tax	2010/10/2012 12:00		200000000000000000000000000000000000000	567		101 A 1000 M 1000 A 101
and exceptional item)	973.15	398.26	362.57	1,371.41	683.20	988.44
Total comprehensive income for the						
period / year [comprising profit for the						
period / year (after tax) and other						
comprehensive income(after tax)]	896.61	373.76	290.02	1,270.37	610.23	728.22
Equity Share Capital	3,790.90	3,780.25	3,591.23	3,790.90	3,591.23	3,758.77
Other equity (excluding revaluation			X11.74.20.77.7.7.7.7.7.7.7.7.7.7.7.7.7.7.7.7.7			
reserve)	25,518.72	24,183.27	17,001.18	25,518.72	17,001.18	23,184.15
Earnings Per Share (EPS)		Not a	nnualized	5 (96 Petro)		Annualized
Basic earnings per share of Rs 2/-each	0.51	0.21	0.20	0.73	0.39	0.55
Diluted earnings per share of Rs2/-each		0.20	0.19	0.69	0.36	0.52
Key numbers of Standalone Financia	Results					ounts in lakhs
1 1200		Quarter ende			ar ended	Year ended
Particulars	30-Sep-24 Unaudited	30-Jun-24 Unaudited	30-Sep-23 Unaudited	30-Sep-24 Unaudited	30-Sep-23 Unaudited	31-Mar-24 Audited
Total Income	10,601.94	6,278.43	5,398.05	16,880.37	10,277.19	22,605.42
Net profit for the period / year (before	Providence of the second	A CONTRACTOR OF THE CONTRACTOR	W. 6000000 1000V	12-Contraction Child		,
	750 70	0.000	0.40.00	1941340909409090	E00 70	2004200

1). The above is an extract from the Unaudited Consolidated and Standalone Financial Results for the Quarter and half year ended September 30, 2024 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The full format of the Unaudited Consolidated and Standalone Financial Results are available at Company's website www.moschip.com and BSE websites. (scrip code 532407). 2). The Unaudited Consolidated and Standalone Financial Results are prepared in accordance with the Indian

347.80

347.80

346.38

346.38

1,101.52

1,101.52

753.72

753.72

Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules thereunder, other accounting principles generally accepted in India and regulations issued by the Securities and Exchange Board of India ("SEBI"). 3). The Unaudited Consolidated Financial Results for the Quarter and Half year ended September 30, 2024 have

been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meetings held on October 24, 2024. The statutory auditors have carried out review of these Consolidated and Standalone Financial Results and have issued an unmodified report on these results.

Place: Hyderabad Date: October 24, 2024

tax and after exceptional item)

And exceptional item)

Net profit for the period / year (after tax

Srinivasa Kakamanu MD & CEO

562.78

562.78

621.92

621.92



**ICRA** Limited

Corporate Identity Number (CIN): L74999DL1991PLC042749 Registered Office: B-710, Statesman House, 148, Barakhamba Road, New Delhi-110001

Telephone No.:+91-11-23357940; Website: www.icra.in; Email ID: investors@icraindia.com EXTRACT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS

FOR THE QUARTER AND SIX MONTHS ENDED SEPTEMBER 30, 2024

S. No.	Particulars	Quarter ended September 30, 2024 (Unaudited)	Six months ended September 30, 2024 (Unaudited)	Quarter ended September 30, 2023 (Unaudited)
1.	Total income from operations	12,612.02	The state of the s	10,485.01
2	Net profit / (loss) for the period (before tax, exceptional and/ or extraordinary items)	5,695.26	10,415.94	4,726.75
3	Net profit / (loss) for the period before tax (after exceptional and/ or extraordinary items)	5,695.26	10,415.94	4,726.75
4	Net profit / (loss) for the period after tax (after exceptional and/ or extraordinary items)	3,710.49	7,299.36	3,214.57
5	Total comprehensive income for the period [comprising profit/ (loss) for the period (after tax) and Other comprehensive income (after tax)]	3,717.52	7,297.11	3,186.29
6	Equity share capital	965.12	965.12	965.12
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet	82	-	
8	Earnings per share (of ₹ 10/- each) (not annualized)			3
	Basic (₹):	38.18	75.10	33.03
	Diluted (₹):	38.11	75.01	33.03

## EYTPACT OF STANDALONE LINAUDITED FINANCIAL PESULTS

				(₹ in lakhs
S. No.	Particulars	Quarter ended September 30, 2024 (Unaudited)	Six months ended September 30, 2024 (Unaudited)	Quarter ended September 30, 2023 (Unaudited)
1	Total income from operations	7,207.96	13,528.39	5,822.90
2	Net profit / (loss) for the period (before tax, exceptional and/ or extraordinary items)	6,495.66	9,626.82	5,262.73
3	Net profit / (loss) for the period before tax (after exceptional and/ or extraordinary items)	6,495.66	9,626.82	5,262.73
4	Net profit / (loss) for the period after tax (after exceptional and/ or extraordinary items)	5,032.51	7,504.02	4,334.44
5	Total comprehensive income for the period [comprising profit/ (loss) for the period (after tax) and Other comprehensive income (after tax)]	5,027.86	7,511.23	4,305.70
6	Equity share capital	965.12	965.12	965.12
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet		SZ.	
8	Earnings per share (of ₹ 10/- each) (not annualized)			
	Basic (₹):	52.32	78.01	45.06
	Diluted (₹):	52.24	77.92	45.06

1. The above is an extract of the detailed format of Quarterly and Six Months Consolidated and Standalone Unaudited Financial Results filed with the Stock Exchanges under Regulation 33 of the Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Statutory Auditors of the Company have carried out limited review of the Consolidated and Standalone Financial Results for the quarter and six months ended September 30, 2024. The full format of the Quarterly and Six Months ended Consolidated and Standalone Unaudited Financial Results and Limited Review Report thereon are available on the Stock Exchange websites at www.nseindia.com and www.bseindia.com and under the Investors section on the Company's website www.icra.in.

By Order of the Board of Directors

Place : Mumbai Date : October 25, 2024 Managing Director & Group C.E.O. (DIN: 09371341)

Ramnath Krishnan

STEL Holdings Limited CIN: L65993KL1990PLC005811 | Regd. Office: 24/1624, Bristow Road, Willingdon Island, Cochin - 682003, Kerala. Email: secretarial@stelholdings.com. Website: www.stelholdings.com

		STANDALONE				CONSOLIDATED			
	PARTICULARS	QUARTE	R ENDED HALF YEAR ENDED YEAR ENDE		YEAR ENDED	AR ENDED QUARTER ENDED		HALF YEAR ENDED	YEAR ENDED
		30.09.2024	30.09.2023	30.09.2024	31.03.2024	30.09.2024	30.09.2023	30.09.2024	31.03.2024
		UNAUDITED	UNAUDITED	UNAUDITED	AUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
1	Total Income from Operations	777.68	416.84	816.41	1,846.41	777.68	416.84	816.41	1,846.41
2	Net Profit / (Loss) from Ordinary activities before Tax	764.06	399.54	776.41	1,774.90	763.87	399.31	776.05	1,773.98
3	Net Profit / (Loss) for the period after Tax	571.72	298.85	580.64	1,328.25	571.53	298.65	580.28	1,327.33
4	Total Comprehensive Income for the period	38,827.39	14,284.87	59,975.10	68,954.62	38,827.20	14,284.67	59,974.74	68,953.70
5	Equity Share Capital	1845.54	1845.54	1845.54	1,845.54	1845.54	1845.54	1845.54	1,845.54
6	Reserves (Excluding Revaluation Reserve)	-	-	2,08,513.10	148,537.99	-	-	2,08,502.77	1,48,528.08
7 (i)	Earnings Per Share (before extraordinary items) (of ₹10 each) Basic & Diluted	3.10	1.62	3.15	7.20	3.10	1.62	1.74	7.19
7 (ii)	Earnings Per Share (after extraordinary items) (of ₹10 each) Basic & Diluted	3.10	1.62	3.15	7.20	3.10	1.62	1.74	7.19

1. The above results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on October 25, 2024. The consolidated financial results for the three months and half year ended September 30, 2024 has been compiled by the management in accordance with Ind AS and have not been subjected to audit.

2. The above is an extract of the detailed format of Quarter and Half year ended Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirments) Regulations, 2015. The detailed financial results are available on the website of the stock exchanges i.e www.bseindia.com & www.nseindia.com and on the Company's website (www.stelholdings.com)

For and on behalf of the Board of Directors

October 25, 2024

Abraham Ittyipe (DIN 02717344) Whole-time Director

# 6 glenmark LIFE SCIENCES

## Glenmark Life Sciences Limited

Registered Office: Plot No. 170-172, Chandramouli Industrial Estate, Mohol Bazarpeth, Solapur-413 213, India.

Corporate Office: 4<sup>th</sup> Floor, OIA House, 470, Cardinal Gracious Road, Andheri (E), Mumbai-400 099, India.

Phone No.: +91 22 68297979; CIN: L74900PN2011PLC139963; Website: www.glenmarklifesciences.com; Email: complianceofficer@glenmarklifesciences.com

### UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30th SEPTEMBER, 2024 (₹ in Millions, unless otherwise stated)

34230			Quarter ended		Half Year	Ended	Year ended
Sr. No.	Particulars	30 Sep'24	30 Jun'24	30 Sep'23	30 Sep'24	30 Sep'23	31 Mar'24
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income						
	Revenue from Operations	5,068.79	5,886.16	5,953.63	10,954.95	11,738.13	22,832.14
	Other Income	85.33	54.93	53.69	140.26	72.20	120.42
	Total Income	5,154.12	5,941.09	6,007.32	11,095.21	11,810.33	22,952.56
11	Expenses						
	Cost of Materials Consumed	2,390.77	2,463.55	2,694.04	4,854.32	5,676.17	10,585.80
	Changes in Inventories of Finished Goods and Work-in-Progress	(138.81)	414.34	36.76	275.53	(464.98)	(565.70)
	Employee Benefits Expense	624.39	568.44	667.14	1,192.83	1,148.46	2,581.56
	Finance Costs	3.43	3.53	3.99	6.96	7.95	15.46
	Depreciation and Amortisation Expense	150.93	143.87	131.29	294.80	257.41	534.52
	Other Expenses	848.85	844.98	884.85	1,693.83	1,776.03	3,488.02
	Total Expenses	3,879.56	4,438.71	4,418.07	8,318.27	8,401.04	16,639.66
Ш	Profit Before Tax (I-II)	1,274.56	1,502.38	1,589.25	2,776.94	3,409.29	6,312.90
IV	Tax Expenses						
	Current Tax	302.40	375.17	387.00	677.57	822.99	1,522.14
	Deferred Tax	19.00	12.38	14.88	31.38	44.43	81.88
	Total Tax Expenses	321.40	387.55	401.88	708.95	867.42	1,604.02
٧	Profit for the Period / Year (III-IV)	953.16	1,114.83	1,187.37	2,067.99	2,541.87	4,708.88
VI	Other Comprehensive Income (OCI)						
	Items that will not be reclassified to profit or loss						
	(a) Re-measurement of the post-employment benefit obligation	(7.28)	(2.33)	(25.98)	(9.61)	(26.95)	(72.99)
	(b) Income tax relating to the above	1.91	0.59	6.09	2.50	6.33	18.37
	Total Other Comprehensive Income / (Loss)	(5.37)	(1.74)	(19.89)	(7.11)	(20.62)	(54.62)
VII	Total Comprehensive Income for the Period / Year (V+VI)	947.79	1,113.09	1,167.48	2,060.88	2,521.25	4,654.26
VIII	Earnings per equity share (Face Value of ₹ 2/- each) (Not Annualised except for the year ended 31st March)						
	(a) Basic (in ₹)	7.78	9.10	9.69	16.88	20.75	38.43
	(b) Diluted (in ₹)	7.75	9.08	9.69	16.83	20.75	38.38
IX	Paid up Equity Share Capital, Equity Shares of ₹ 2/- each	245.06	245.05	245.05	245.06	245.05	245.05
X	Other Equity excluding Revaluation Reserve		il .				23,078.17

See accompanying notes to the Financial Results UNAUDITED BALANCE SHEET AS AT 30TH SEPTEMBER, 2024

(₹ in Millions) As at

Particulars	As at 30th September 2024 (Unaudited)	As at 31* March 2024 (Audited)
ASSETS		ACT
Non-Current Assets		
Property, Plant and Equipment	8.037.42	7,950.12
Capital Work-in-Progress	1,413.82	1,011.85
Intangible Assets	111.20	100.52
Intangible Assets Under Development	61.50	48.01
Financial Assets		
(i) Investments	0.77	0.77
(ii) Other Financial Assets	110.44	110.30
Income Tax Assets(Net) Other Non-Current Assets	75.69 77.17	36.72 85.84
Total Non-Current Assets	9,888.01	9,344.13
Current Assets	17470,037.3	0.585.5047.55
Inventories	6,892.03	6,665.91
Financial Assets	167 65 (T. 1865) (T. 1865)	
(i) Trade Receivables	7,751.27	7,654.32
(ii) Cash and Cash Equivalents	4,461.17	3,014.14
(iii) Bank Balance other than Cash and Cash Equivalents	1.75	1.80
(iv) Others Financial Assets	839.10	903.68
Other Current Assets	1,015.26	920.14
Total Current Assets	20,960.58	19,159.99
Total Assets	30,848.59	28,504.12
EQUITY AND LIABILITIES		
Equity		
Equity Share Capital	245.06	245.05
Other Equity	25,139.74	23,078.17
Total Equity	25,384.80	23,323.22
Liabilities		
Non-Current Liabilities		
Financial Liabilities		
(i) Lease Liabilities	133.80	147.61
Provisions	175.92	157.71
Deferred Tax Liabilities (Net)	516.73	487.85
Total Non-Current Liabilities	826.45	793.17
Current Liabilities		
Financial Liabilities		
(i) Lease Liabilities	25.97	23.87
(ii) Trade Payables:	30,000	
<ul> <li>(a) Total Outstanding dues of Micro &amp; Small Enterprises</li> </ul>	213.46	93.82
<ul><li>(b) Total Outstanding dues of Other than Micro &amp; Small Enterprises</li></ul>	3,768.19	3,592.79
(iii) Other Financial Liabilities	383.19	402.68
Other Current Liabilities	108.08	154.23
Provisions	138.45	120.34
Total Current Liabilities	4,637.34	4,387.73
Total Liabilities	5,463.79	5,180.90
Total Equity and Liabilities	30,848.59	28,504.12

UNAUDITED CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30TH SEPTEMBER, 2024

(₹ in Millions) Half Year Half Year Ended Ended **Particulars** 30th Sep'23 30th Sep'24 A. CASH FLOW FROM OPERATING **ACTIVITIES Profit Before Tax** 2,776.94 3,409.29 Adjustments for: Loss / (Gain) on Sale / Discard of Property, 11.30 0.09 Plant and Equipment (Net) Depreciation and Amortisation Expense 294.80 257.41 (10.43)Unrealised foreign exchange (gain) / loss (2.65)Provision for Gratuity and Compensated 37.85 39.49 Absence Provision for Doubtful Debts 0.64 20.33 14.05 Shared Based Payment Expenses Interest Income (125.25)(74.91)Finance Costs 6.96 7.95 Operating Profit before Working Capital 3,000.59 3,663.27 Adjustments for Working Capital changes: (Increase)/Decrease in Trade Receivables (97.59)(27.32)(Increase)/Decrease in Other Assets (30.68)(267.74)(226.12)(653.41)(Increase)/Decrease in Inventories Increase/(Decrease) in Trade and Other 266.17 108.25 Payables 2,912.37 2,823.05 Cash Generated from Operations Taxes Paid (Net of Refunds) (716.55)(660.87)2,195.82 2,162.18 Net Cash Generated from Operating Activities B. CASH FLOW FROM INVESTING **ACTIVITIES** Purchase of Property, Plant and Equipment (856.37)(627.19)and Intangible Assets (including Capital Work in Progress) Interest Received 125.25 74.91 (731.12) (552.28)Net Cash used in Investing Activities C. CASH FLOW FROM FINANCING ACTIVITIES Proceeds from exercise of employee stock Principal repayment of Lease Liabilities (11.71)(10.71)(6.96)(7.95)Interest payment of Lease Liabilities Net Cash used in Financing Activities (17.67)(18.66)Net Increase/(Decrease) in Cash and 1,447.03 1,591.24 Cash Equivalents 3,014.14 2,838.23 Opening Balance of Cash and Cash Equivalents 4,461.17 4,429.47 Closing Balance of Cash and Cash Equivalents

- Notes: 1. The Financial Results have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 read with relevant
- rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). 2. The above Financial Results were reviewed by Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on October 24,
- 2024. These results have been subjected to limited review by statutory auditor who have issued an unmodified conclusion on the said results. The Company has identified only one segment i.e. Active Pharmaceutical Ingredient (API) as reporting segment based on the information reviewed by Chief Operating Decision
- Maker (CODM). As at September 30, 2024, pursuant to Employee Stock Option Plan 2021 8,72,022 options were outstanding, which upon exercise are convertible into equivalent number of

For Glenmark Life Sciences Limited Yasir Rawjee Managing Director & CEO

Mumbai, October 24, 2024

equity share.

financialexp.epapr.in \_\_\_\_\_\_



